Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• المؤلفون الرئيسيون: Qiao Liu (مؤلف), Zhen Zhou (مؤلف), Xia Luo (مؤلف), Lidan Yi (مؤلف), Liubao Peng (مؤلف), Xiaomin Wan (مؤلف), Chongqing Tan (مؤلف), Xiaohui Zeng (مؤلف)
• التنسيق: كتاب
• منشور في: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...